Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 1

Status

Completed 2Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 1Myeloid 1

Conditions

Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 4Recurrence 3Myeloproliferative Disorders 3Lymphoma 3Primary Myelofibrosis 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Cyclophosphamide 62Rituximab 47fludarabine 35fludarabine phosphate 27obinutuzumab 17Mycophenolic Acid 16ibrutinib 15Whole-Body Irradiation 15Lenalidomide 15Specimen Handling 14Prednisone 14Etoposide 14venetoclax 13pirtobrutinib 13Doxorubicin 13pembrolizumab 12Tacrolimus 12Magnetic Resonance Spectroscopy 11Granulocyte Colony-Stimulating Factor 11Filgrastim 11Biopsy 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10Melphalan 10X-Rays 9Bendamustine Hydrochloride 9polatuzumab vedotin 8glofitamab 8acalabrutinib 8Immunotherapy, Adoptive 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Lymphoma, Non-Hodgkin × parsaclisib × 1 year × Clear all
NCT04661007 2026-05-18

J-MIND

Incyte Corporation

Phase 1/2 Active not recruiting
72 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04809467 2026-02-04

topMIND

Incyte Corporation

Phase 1/2 Terminated
54 enrolled 23 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04509700 2025-12-10

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Incyte Corporation

Phase 2 Active not recruiting
112 enrolled
LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myeloproliferative Disorders

NCT02998476 2025-08-22

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

Incyte Corporation

Phase 2 Completed
60 enrolled 15 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03039114 2025-08-21

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Incyte Corporation

Phase 1 Completed
26 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡